- Home
- MYGN vs STC Comparison
MYGN vs STC Comparison
Compare MYGN & STC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYGN | STC |
|---|---|---|
| Founded | 1991 | 1893 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 2.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYGN | STC |
|---|---|---|
| Price | $7.02 | $71.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | $11.82 | ★ $77.50 |
| AVG Volume (30 Days) | ★ 1.0M | 238.7K |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 2.85% |
| EPS Growth | N/A | ★ 69.60 |
| EPS | N/A | ★ 3.60 |
| Revenue | $825,300,000.00 | ★ $2,796,513,000.00 |
| Revenue This Year | $0.10 | $17.67 |
| Revenue Next Year | $5.28 | $10.14 |
| P/E Ratio | ★ N/A | $20.45 |
| Revenue Growth | 0.21 | ★ 16.09 |
| 52 Week Low | $3.76 | $56.39 |
| 52 Week High | $15.47 | $78.61 |
Technical Indicators
Market Signals| Indicator | MYGN | STC |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 42.55 |
| Support Level | $7.15 | $70.00 |
| Resistance Level | $7.43 | $74.91 |
| Average True Range (ATR) | 0.28 | 2.47 |
| MACD | -0.03 | -0.47 |
| Stochastic Oscillator | 21.20 | 19.18 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About STC Stewart Information Services Corporation
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.